Shi GY, Yuan Z, Yang LL, Xie JD. Efficacy of octreotide for treatment of cirrhosis with refractory ascites: A meta-analysis.
Shijie Huaren Xiaohua Zazhi 2015;
23:4411-4417. [DOI:
10.11569/wcjd.v23.i27.4411]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the efficacy and safety of octreotide in the treatment of cirrhosis with refractory ascites.
METHODS: PubMed, EMBASE, CBM, CNKI, VIP and Wanfang Database were searched to retrieved studies evaluating the efficacy of octreotide in the treatment of cirrhosis with refractory ascites. All the related data that met our standards were extracted. The quality of the included trials was evaluated according to the Jadad score. RevMan 5.2 software was used for meta-analysis.
RESULTS: A total of 9 randomized controlled trials involving 696 patients were included. The results of meta-analysis showed that the octreotide group was superior to the control group in treatment efficiency (OR = 3.18, 95%CI: 2.03-4.97, P < 0.00001), weight reduction (MD = -8.75, 95%CI: -11.25--6.25, P < 0.00001), ascites reduction (SMD = -31.8, 95%CI: -35.23--28.37, P < 0.00001), decreased abdominal girth (SMD = -8.75, 95%CI: -11.55--5.95, P < 0.00001), increased blood urea nitrogen (BUN) (MD = -1.18, 95%CI: -2.31--0.06, P = 0.04) and 24 h urine volume (SMD = 8.18, 95%CI: 3.69-12.67, P = 0.0004), but there was no statistical difference in serum creatinine (sCr) or portal vein trunk diameter (PVD).
CONCLUSION: Current evidence suggests that octreotide could improve treatment efficiency in terms of weight reduction, ascites reduction, decreased abdominal girth, increased BUN and 24 h urine volume.
Collapse